Skip to main content

Cel Sci Corp

CVM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000725363

In the last 90 days, Cel Sci Corp insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $2.08M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Cel Sci Corp changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of CVM: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders85178−6
Shares7.67M1.50K6.46M−1.21M (−15.7%)
Value$34.5M$7.00K$20.0M−$14.5M (−42.1%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (10)

Institutions that held Cel Sci Corp at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to CVM in Q3 2022
InstitutionSharesValue% of portfolio
Bridgeway Capital Management, LLC98,300$304.0K0.01%
Plotkin Financial Advisors, LLC92,008$284.3K0.29%
Qube Research & Technologies Ltd30,181$93.0K0.00%
Hartline Investment Corp16,170$50.0K0.04%
Balyasny Asset Management LLC15,491$48.0K0.00%
Csenge Advisory Group10,700$33.0K0.00%
MML Investors Services, LLC10,150$31.0K0.00%
Almanack Investment Partners, LLC.4,500$16.0K0.00%
Gables Capital Management Inc.800$2.00K0.00%
Householder Group Estate & Retirement Specialist, LLC211$00.00%

Sold out (16)

Institutions that held Cel Sci Corp at the end of Q2 2022 and filed for Q3 2022 without it.

Not filed for Q3 2022 yet (1)

Institutions that held Cel Sci Corp at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CVM in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Brewin Dolphin Wealth Management Ltd1,500$7.00K